GMAB logo

Genmab A/S (GMAB)

$51.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GMAB

Market cap

$32.43B

EPS

0.24

P/E ratio

155.1

Price to sales

40.07

Dividend yield

--

Beta

0.730811

Price on GMAB

Previous close

$51.57

Today's open

$50.90

Day's range

$50.86 - $52.08

52 week range

$23.62 - $59.97

Profile about GMAB

CEO

JanG.J. van de Winkel

Employees

3029

Headquarters

Valby,

Exchange

Nasdaq Global Select

Shares outstanding

624058550

Issue type

American Depository Receipt

GMAB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on GMAB

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; November 18, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 4,993 restricted stock units and 4,607 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

news source

GlobeNewsWire • 5 hours ago

news preview

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 11, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

news source

GlobeNewsWire • Nov 10, 2026

news preview

What Genmab A/S (GMAB) Said on Its Q3 Earnings Call

Genmab A/S NASDAQ: GMAB reported 22% revenue growth for the first nine months of 2026 and said it expects full-year revenue to land in the upper part of its existing guidance range, as sales of EPKINLY and royalty income supported growth.

news source

MarketBeat • Nov 5, 2026

news preview

Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript

Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 68th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually. The breadth of data to be shared at ASH reflects continued progress across the comprehensive epcoritamab development program, incl.

news source

Business Wire • Nov 4, 2026

news preview

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

Genmab shares have doubled in three months after three successful Phase 3 cancer drug trials in October. The Danish biotech is using royalty income from drugs such as Darzalex to fund a shift toward owning more of the medicines it develops and sells.

news source

CNBC • Nov 3, 2026

news preview

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.

news source

Barrons • Oct 28, 2026

news preview

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or co-develops.

news source

MarketBeat • Oct 28, 2026

news preview

Genmab Stock Hits 52-Week High - Here's Why

Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting EGFR and LGR5.

news source

Benzinga • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Genmab A/S

Open an M1 investment account to buy and sell Genmab A/S commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GMAB on M1